Evidence map›Paper›PMID 19956432›Full record

ArticleAmerican journal of translational research2009

Integrin signaling aberrations in prostate cancer.

Hira Lal Goel, Naved Alam, Isaac N S Johnson, Lucia R Languino

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Aberrant BAF57 signaling facilitates prometastatic phenotypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hira Lal GoelDepartment of Cancer Biology, Prostate Cancer Discovery and Development Program, Cancer Center, University of Massachusetts Medical School Worcester, MA 01605, USA.
Naved Alam
Isaac N S Johnson
Lucia R Languino
University of Massachusetts Chan Medical School · US

Funding

INTEGRIN SIGNALING PATHWAYS IN PROSTATE CANCERR01CA089720 · NCI · YALE UNIVERSITY · PI LANGUINO, LUCIA R. · 2001 to 2014
$2.8M
Beta1 Integrins and IGF-l Receptor in Prostate CancerR01CA109874 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LANGUINO, LUCIA R. · 2005 to 2015
$2.7M
NCI NIH HHS R01 CA089720NCI NIH HHS R01 CA109874
6 · The paper itself

Abstract

Integrins are cell surface receptors for extracellular matrix proteins and play a key role in cell survival, proliferation, migration and gene expression. Integrin signaling has been shown to be deregulated in several types of cancer, including prostate cancer. This review is focused on integrin signaling pathways known to be deregulated in prostate cancer and known to promote prostate cancer progression.

Identifiers

PMID19956432
PMCPMC2757165
OpenAlexW1605932598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.